

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4860631

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ATSUSHI WATANABE	02/20/2018
YUUKI SATO	02/20/2018
KEIJI OGURA	02/20/2018
YOSHIYUKI TATSUMI	02/20/2018
RECEIVING PARTY DATA	
Name:	KAKEN PHARMACEUTICAL CO., LTD.
Street Address:	28-8, HONKOMAGOME 2-CHOME, BUNKYO-KU
City:	TOKYO
State/Country:	JAPAN
Postal Code:	113-8650
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15759125
CORRESPONDENCE DATA	
Fax Number:	(312)616-5700
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(312) 616-5600
Email:	mgreer@leydig.com
Correspondent Name:	JOHN KILYK, JR.
Address Line 1:	LEYDIG, VOIT & MAYER, LTD.
Address Line 2:	TWO PRUDENTIAL PLAZA, SUITE 4900
Address Line 4:	CHICAGO, ILLINOIS 60601-6731
ATTORNEY DOCKET NUMBER:	738459
NAME OF SUBMITTER:	JOHN KILYK, JR.
SIGNATURE:	/John Kilyk, Jr./
DATE SIGNED:	03/09/2018
Total Attachments: 3	
source=Assignment#page1.tif	
source=Assignment#page2.tif	

ASSIGNMENT

WHEREAS, I/WE

(1) Atsushi WATANABE of c/o KAKEN PHARMACEUTICAL CO., LTD., Drug Research Center, 14, Shinomiyaminamigawara-cho, Yamashina-ku, Kyoto-shi, Kyoto 607-8042 Japan,

(2) Yuuki SATO of c/o KAKEN PHARMACEUTICAL CO., LTD., Drug Research Center, 14, Shinomiyaminamigawara-cho, Yamashina-ku, Kyoto-shi, Kyoto 607-8042 Japan,

(3) Keiji OGURA of c/o KAKEN PHARMACEUTICAL CO., LTD., Drug Research Center, 14, Shinomiyaminamigawara-cho, Yamashina-ku, Kyoto-shi, Kyoto 607-8042 Japan, and

(4) Yoshiyuki TATSUMI of c/o KAKEN PHARMACEUTICAL CO., LTD., Drug Research Center, 14, Shinomiyaminamigawara-cho, Yamashina-ku, Kyoto-shi, Kyoto 607-8042 Japan,

hereinafter referred to as Assignor, have invented a certain invention entitled:

BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME

for which invention an application for a U.S. patent was filed on March 9, 2018, under U.S. Application No. 15/759,125, as the U.S. national phase of International Application No. PCT/JP2016/077029, which was filed on September 14, 2016, and

WHEREAS,

KAKEN PHARMACEUTICAL CO., LTD., of 28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo 113-8650 Japan,

hereinafter referred to as Assignee, is desirous of acquiring the entire right, title, and interest in, to, and under the invention described in the patent application, including the entire priority right derived from the application,

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,

Assignor assigns and transfers to Assignee and Assignee's legal representatives, successors, and assigns the entire right, title, and interest in, to, and under the invention, the referenced patent application, other such applications (e.g., provisional applications, non-provisional applications, continuations, continuations-in-part, divisionals, reissues, reexaminations, national and regional phase applications, petty patent applications, and utility model applications) that may be filed in the U.S. and/or any country foreign to the U.S. on the invention, the patents that may issue thereon, and the patents as may be modified as the result of applicable procedures (e.g., supplemental examinations, ex parte reexaminations, inter partes reexaminations, inter partes reviews, post-grant reviews, and oppositions),

Assignor conveys to the Assignee the right to make applications in Assignee's own behalf for protection of the invention in the U.S. and countries foreign to the U.S. and to claim priority to the referenced patent application and other such applications that may be filed in the U.S. or any country foreign to the U.S. on the invention under the Patent Cooperation Treaty, the Paris Convention, and any other international arrangements,

Assignor will not execute any writing or do any act conflicting with the terms of this assignment,

Assignor will at any time upon request, without further or additional consideration, but at the expense of the Assignee, execute such additional assignments and other writings and do such additional acts as the Assignee may deem necessary or desirable to pursue the patent applications identified herein, including, but not limited to, rendering all necessary assistance in making applications for and obtaining patents that may issue thereon in the U.S. and any countries foreign to the U.S. on the invention, and in enforcing any rights accruing as a result of such applications or patents, by, for example, executing statements and other affidavits,

Assignor and Assignee agree the terms of this assignment shall bind, and inure to the benefit of, the legal representatives, successors, and assigns of all parties hereto,

Assignor authorizes Assignee to insert in this assignment the number and filing date of the application if the number and filing date of the application are not recited herein at the time of execution of this assignment by any or all of the parties hereto,

Assignor and Assignee agree that U.S. law governs this assignment, and

Assignee acknowledges and accepts this assignment.

IN WITNESS WHEREOF, Assignor has hereunder set his/her hand on the date shown below.

Date Feb. 20, 2018

Atsushi Watanabe
Assignor: Atsushi WATANABE

Date Feb. 20, 2018

Noriyuki Kamei
Witness: Noriyuki KAMEI

Date Feb. 20, 2018

Takeshi Asano
Witness: Takeshi ASANO

Date Feb. 20, 2018

Yuuki SATO
Assignor: Yuuki SATO

Date Feb. 20, 2018

Noriyuki Kamei
Witness: Noriyuki KAMEI

Date Feb. 20, 2018

Takeshi Asano
Witness: Takeshi ASANO

Date Feb. 20, 2018

Keiji OGURA
Assignor: Keiji OGURA

Date Feb. 20, 2018

Noriyuki Kamei
Witness: Noriyuki KAMEI

Date Feb. 20, 2018

Takeshi Asano
Witness: Takeshi ASANO

Date Feb. 20, 2018

Yoshiyuki TATSUMI
Assignor: Yoshiyuki TATSUMI

Date Feb. 20, 2018

Noriyuki Kamei
Witness: Noriyuki KAMEI

Date Feb. 20, 2018

Takeshi Asano
Witness: Takeshi ASANO